asenapine / Generic mfg. - LARVOL DELTA

Comparative efficacy of antipsychotics for reducing aggression in schizophrenia: systematic review and network meta-analysis. (PubMed, Br J Psychiatry) - "Antipsychotics reduced hostility and aggressive behaviour in predominantly short- to medium-term studies. Clozapine, paliperidone and olanzapine appeared most effective, although low-certainty evidence limits conclusions about differences between antipsychotics. Further trials with aggressive behaviour as the primary outcome and longer follow-up are needed."

Journal • Retrospective data • Review • CNS Disorders • Psychiatry • Schizophrenia

Use of Electroconvulsive Therapy for Treatment-Resistant Schizophrenia in a Patient Unable to Tolerate Clozapine Due to Clozapine-Associated Hyponatremia: A Case Report. (PubMed, Case Rep Psychiatry) - "Despite prior antipsychotic trials with haloperidol, asenapine, olanzapine, and chlorpromazine, the patient had persistent auditory hallucinations and paranoid delusions. At 5 months post-ECT, he remained free from readmission and without recurrence of his positive symptoms. This case highlights the potential role of ECT as a therapeutic consideration for select patients with refractory psychosis when clozapine cannot be safely continued due to medically significant adverse effects such as hyponatremia."

Journal • Cardiovascular • CNS Disorders • Heart Failure • Pain • Psychiatry • Schizophrenia

Enantioselective Total Synthesis of (+)-and (-)-Asenapine. (PubMed, J Org Chem) - "The asymmetric 1,4-addition of vinyl Grignard provided the diastereomers in excellent yield with a 5.9:1 dr and 98% ee. The opposite isomer, (-)-asenapine, was accessed using the enantiomeric Evans auxiliary under identical conditions."

Journal • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry • Schizophrenia

Evidence based interventions for bipolar disorder across phases and age groups: living umbrella review, evaluation, analysis, and communication hub (U-REACH) project. (PubMed, BMJ) - "The EBI-BD tool can help clinicians make evidence based, personalised treatment decisions for bipolar disorder. This resource can inform clinical guidelines and provides a foundation for continuously improving bipolar disorder care as new evidence emerges."

Journal • Review • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

Efficacy, acceptability, and related outcomes of pharmacological interventions for acute bipolar mania: a systematic review and dose-related network meta-analysis across different age groups. (PubMed, J Affect Disord) - "Our findings are consistent with previous NMAs and current guidelines, expanding the current knowledge base while concurrently appraising different drugs, doses, and age groups."

Journal • Retrospective data • Review • Bipolar Disorder • CNS Disorders • Mood Disorders • Pediatrics • Psychiatry

A Case of Meige Syndrome in a Pediatric Patient With Schizophrenia. (PubMed, Clin Case Rep) - "We stopped giving him the same medications that had been used during his previous hospitalizations (risperidone, olanzapine, aripiprazole, lurasidone, and paliperidone, paliperidone palmitate (a long-acting injectable), asenapine, and blonanserin). We then started giving him clozapine, gradually increasing the dose to 125 mg. Following this treatment intervention, the dystonic symptoms resolved completely, and the psychiatric symptoms stabilized."

Journal • CNS Disorders • Dystonia • Movement Disorders • Pediatrics • Psychiatry • Schizophrenia

Effects of add-on asenapine therapy on sleep in schizophrenia: a case series. (PubMed, Sleep Biol Rhythms) - "These preliminary findings suggest that ASE may be a viable adjunctive treatment option for patients with schizophrenia experiencing insomnia and positive symptoms. Further studies with larger, controlled samples are needed to validate these effects."

Journal • CNS Disorders • Insomnia • Psychiatry • Schizophrenia • Sleep Disorder

Diagnosis and Medication Treatment of Schizophrenia in Adolescents. (PubMed, Drugs) - "Randomized controlled trials and open-label studies support the efficacy of risperidone, aripiprazole, olanzapine, quetiapine, paliperidone, lurasidone, and brexpiprazole in reducing psychotic symptoms in adolescents. In contrast, ziprasidone and asenapine have not demonstrated clear benefit in treatment of schizophrenia in youth. Similar to studies in adults, evidence from pediatric clinical trials suggests that clozapine remains the most effective option for treatment-resistant adolescent schizophrenia, although its use requires close monitoring for hematologic and other adverse effects...However, the relative paucity of pediatric-specific data compared with adult populations underscores the importance of continued research to guide clinical practice. In the meantime, accurate diagnosis, early intervention, and vigilant monitoring of both therapeutic response and side effects remain essential to optimizing outcomes for youth with schizophrenia."

Journal • Review • Anesthesia • CNS Disorders • Hematological Disorders • Metabolic Disorders • Pediatrics • Psychiatry • Schizophrenia

RAKGEORREC: Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR. (clinicaltrials.gov) - P4 | N=84 | Active, not recruiting | Sponsor: Dr. Stavroula Rakitzi | Recruiting ➔ Active, not recruiting | N=40 ➔ 84

Enrollment change • Enrollment closed • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry • Schizophrenia

Efficacy and safety of pharmacological interventions for the maintenance of bipolar disorder: A systematic review and dose-related network meta-analysis across different age groups. (PubMed, J Affect Disord) - "Our findings are consistent with previous NMAs and current guidelines, yet they expand current knowledge by concurrently appraising different drugs, doses, and age groups."

Journal • Retrospective data • Review • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Pediatrics • Psychiatry

Female Sexual Dysfunction Induced by Second-Generation Antipsychotic Drugs-A Disproportionality Analysis Based on the FAERS Database. (PubMed, Schizophr Bull) - "This pharmacovigilance study highlights significant associations between specific SGAs and female sexual dysfunction. Disproportionality signals vary by drug, symptom type, and prolactin-related mechanisms. Clinicians should consider sexual side effects in treatment decisions and monitor patients accordingly. Further prospective studies are warranted."

Journal • CNS Disorders • Mental Retardation • Psychiatry • Sexual Disorders

Efficacy and Safety of Asenapine in Bipolar Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (PubMed, Psychopharmacol Bull) - "Adverse events were more frequent with asenapine. Asenapine is an effective short-term treatment for acute mania in bipolar disorder, with tolerability considerations."

Clinical • Journal • Retrospective data • Review • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

Antipsychotics in Children and Adolescents with Schizophrenia-Spectrum Disorders: A Systematic Review, Meta-Analysis, and Long-Term Prospective Evidence. (PubMed, J Child Adolesc Psychopharmacol) - "Several SGAs produce short-term symptom reductions versus placebo in children and adolescents with schizophrenia-spectrum disorders, with heterogeneity in TEAE risk across agents. Evidence for long-term maintenance and continuation remains limited, underscoring the need for adequately powered randomized continuation trials to guide sustained treatment in this population."

Journal • Retrospective data • Review • CNS Disorders • Mental Retardation • Psychiatry • Schizophrenia

Asenapine for delirium in patients with cancer: A scoping review. (PubMed, PCN Rep) - "The current evidence is limited in quantity and quality, and no preventive studies were identified. While preliminary findings suggest that sublingual asenapine may be useful and well-tolerated for treating delirium in patients with cancer, further high-quality studies are warranted."

Journal • Review • Anesthesia • CNS Disorders • Oncology • Palliative care

Alizarin red S@ZIF-8 composite-modified carbon paste electrode: A novel sensitive sensor for the voltammetric determination of asenapine maleate in human plasma. (PubMed, Mikrochim Acta) - No abstract available

Journal

Allele-specific rescue of neurexin behavioral phenotypes by monoamine-targeting compounds. (PubMed, bioRxiv) - "Multi-behavior testing revealed pharmacological specificity: olanzapine improved both activity and social feeding phenotypes of nrx-1 alleles, while asenapine maleate improved activity, but worsened social feeding, indicating distinct modifier impacts across behavioral domains. Our findings establish monoamine modulation as a conserved compensatory mechanism for neurexin loss, identify olanzapine as a lead compound for targeting neurexin loss, and demonstrate that allele stratification and pharmacogenomic approaches are needed for precision intervention in behavioral conditions."

Journal • Autism Spectrum Disorder • CNS Disorders • Developmental Disorders • Epilepsy • Genetic Disorders • Movement Disorders • Psychiatry • Schizophrenia • Tourette Syndrome • NRXN1

Antipsychotic treatment patterns and cardiometabolic medicine use: current real-world evidence. (PubMed, Epidemiol Psychiatr Sci) - "Use of cardiometabolic medicines is increased among people on long-term antipsychotic treatment. These results highlight the need for active monitoring for cardiometabolic adverse effects, with antipsychotic cessation where possible, or timely interventions to limit morbidity."

HEOR • Journal • Real-world evidence • Retrospective data • Cardiovascular • CNS Disorders • Metabolic Disorders

Efficacy and safety of pharmacological treatments in borderline personality disorder: A systematic review and network meta-analysis. (PubMed, Mol Psychiatry) - "Topiramate (200-250 mg/day, 8-10 weeks), lamotrigine (50-200 mg/day, 8 weeks), and aripiprazole (15 mg/day, 8 weeks) most effectively reduced hostility, aggressiveness, and anger, and improved anger control. Carbamazepine (200-1200 mg/ day, 6 weeks) and asenapine (5-10 mg/day, 12 weeks) improved impulsivity and emotional dysregulation, respectively...Conversely, alprazolam, methylphenidate, haloperidol, and valproate had only low-certainty evidence in unselected BPD samples and should not be prioritised. Prescription should be limited to specific, individualised indications, such as panic, comorbid ADHD, or transient psychotic features, following cautious clinical appraisal."

Journal • Retrospective data • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Borderline Personality Disorder • CNS Disorders • Mood Disorders • Personality Disorder • Psychiatry

An observational study on the effects of as-needed use of various antipsychotic drugs for agitation due to psychotic disorders. (PubMed, Int Clin Psychopharmacol) - "Kaplan-Meier estimates showed mean onset times (minutes) for oral/sublingual drugs as follows: asenapine sublingual, 30.0; olanzapine orally disintegrating tablet, 31.9; quetiapine, 46.6; and risperidone oral solution, 34.5...For injectable antipsychotics, mean onset times were: olanzapine intramuscular, 36.3; haloperidol intramuscular, 47.5; and haloperidol intravenous, 45.0, with no significant differences among them. No serious adverse events were observed. The findings suggest that asenapine sublingual may offer faster calming in patients without refusal, and that future studies with shorter assessment intervals are warranted."

Journal • Observational data • CNS Disorders • Psychiatry

Efficacy and Safety of Cariprazine, Asenapine, Xanomeline-Trospium, and Lumateperone for Acute Exacerbations of Schizophrenia in Adults: A Network Meta-Analysis. (PubMed, Schizophr Bull Open) - "However, further head-to-head comparisons with standard treatments are needed to guide a more evidence-based selection. Future trials with longer durations and more diverse populations are warranted to confirm and extend these findings."

Journal • Retrospective data • CNS Disorders • Psychiatry • Schizophrenia

Grading the Evidence- Bipolar Disorder and Schizophrenia (AACAP 2025) - "FDA approval will also be part of the metric in helping to determine recommendations. Multiple studies are available that are funded by the NIH and FDA for psychosis (primarily schizophrenia) that show high levels of evidence, ie, grades 1A and 1B for benefit with tolerable side effects including newer medications such as lurasidone. Other medications have good efficacy but higher side-effect burdens such as clozapine. Finally, some medications have inadequate separation from placebo and are not approved, such as ziprasidone and asenapine... The field of psychopharmacology for bipolar and psychotic disorders has a number of completed controlled trials that contribute to the evidence base. Clinicians can use the GRADE system to recommend medications based on the balance of efficacy vs adverse event burden to obtain symptom control.BRD, PSY, PTA"

Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Pediatrics • Psychiatry • Schizophrenia

Bipolar disorder in children, adolescents and young adults. Part 2. Therapeutic management. Recommendations under the patronage of the Executive Board of the Polish Psychiatric Association, National Consultants in the field of Psychiatry and National Consultants in Child and Adolescent Psychiatry. (PubMed, Psychiatr Pol) - "Lithium, aripiprazole, quetiapine, risperidone, olanzapine, asenapine, ziprasidone are recommended for the treatment of mania and mixed states. For the treatment of depressive episodes in bipolar disorder in children and adolescents, experts recommend lurasidone as monotherapy or olanzapine + fluoxetine as combination therapy. Although long-term treatment is a key aspect of bipolar disorder management in children and adolescents, consistent efficacy data are still lacking. Safety data indicate that the most commonly reported adverse reactions in children and adolescents treated with mood stabilizers are gastrointestinal and neurological adverse reactions, while the use of antipsychotics is mainly associated with weight gain and sedation."

Clinical guideline • Journal • Review • Anesthesia • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

Analysis of acute pancreatitis caused by multi-acting receptor-targeted antipsychotics using the Japanese claims database. (PubMed, J Affect Disord) - "These results highlight the need for careful monitoring of pancreatitis in patients receiving long-term MARTA therapy. In individuals with risk factors such as obesity, diabetes, or dyslipidemia, the use of MARTA should be considered cautiously. Early detection and appropriate management are essential to reduce the risk of serious outcomes."

Journal • CNS Disorders • Diabetes • Dyslipidemia • Genetic Disorders • Metabolic Disorders • Obesity • Pancreatitis

Glucose dysregulation signals in weight-neutral atypical antipsychotics: A pharmacovigilance-pharmacodynamic evaluation of FAERS data. (PubMed, J Affect Disord) - "Weight-neutral drugs such as ziprasidone, asenapine, lurasidone, and aripiprazole may be associated with glucose dysregulation, underscoring the need for vigilance when switching antipsychotics. This phenomenon might be attributable to their antagonistic effects on 5-HT2C receptors. However, given the exploratory nature of this study, these findings warrant further validation."

Adverse events • Journal • PK/PD data • CNS Disorders

Cults, trauma, and bipolarity: Clinical perspectives through a real case (ECNP 2025) - "The treatment plan involved discontinuing sertraline and starting asenapine 5 mg, which was poorly tolerated. It was then switched to quetiapine, increasing up to 200 mg, leading to normalization of circadian rhythms and progressive resolution of the manic episode...Findings suggest that PTSD exacerbates the outcome of bipolar disorder, as bipolar patients with PTSD are less likely to recover, experience more rapid cycling, have an increased risk of suicide attempts, and suffer from a poorer quality of life [3]. Given the limited literature on the relationship between PTSD and bipolar disorder, and the high comorbidity of both, further research is needed to establish treatment strategies tailored to these patients."

Clinical • Bipolar Disorder • CNS Disorders • Insomnia • Mood Disorders • Post-traumatic Stress Disorder • Psychiatry • Sleep Disorder • Substance Abuse